Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

REPL vs EDIT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

REPL Captures Overall Composite Edge (27.4 SELL vs 48.4 HOLD), While EDIT Leads 4–2 on Growth & Valuation Pillars

REPL Overall Winner 6-Pillar Tally: REPL 2 – 4 EDIT Matrix Metrics: REPL 6 – 2 EDIT

As of Nov 16, 2026, Replimune Group, Inc. (REPL) captures the overall head-to-head institutional edge over Editas Medicine, Inc. (EDIT) on higher Unified Composite conviction (27.4/100 SELL vs. 48.4/100 HOLD) after splitting the core matrix 6–2 (led by Profitability & Quality, Options & Positioning), while EDIT wins 4–2 across the 6-pillar growth and valuation breakdown. REPL trades at $21.54 (N/M Forward P/E, 0.0% operating margin) versus EDIT at $1.91 (N/M Forward P/E, -167.0% operating margin).

  • Composite vs. Pillar Nuance: While EDIT currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. REPL 27.4/100 SELL), REPL captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -167.0% operating margin) and revenue trajectory (+0.0% vs. +37.4% YoY).
  • Technical & Structure Timing Caution: REPL trades in a Markup technical trend (BREAKOUT options phase, RSI 69.6); meanwhile EDIT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About REPL vs EDIT
REPL NASDAQ Head-to-Head Winner
Replimune Group, Inc.
Biological Products, (No Disgnostic Substances)
$21.54
-1.6% 1D
Market Cap $2.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.10β · 100% Vol
Unified Composite Score
27.4 / 100 SELL
Tech 50.0 Fund 34.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (8.3% over 20 days), RSI 70
RSI-14: 69.6 · SMA20: $17.92 · SMA50: $14.89
EDIT NASDAQ
Editas Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.91
-12.21% 1D
Market Cap $336.5M
TTM Revenue $50M
Forward P/E N/M
Beta / 30D Vol 2.32β · 102% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 33.0 Fund 55.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.3%), weak momentum, RSI 33
RSI-14: 33.4 · SMA20: $2.52 · SMA50: $2.61

6-Pillar Scorecard Institutional Category Breakdown (REPL 2 – 4 EDIT)

Columns: Metric · REPL · EDIT
1. Valuation Multiples EDIT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 5.2x
2. Growth & Scale EDIT
Revenue Growth (YoY) +0.0% +37.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $50M
Market Cap $2.1B $336.5M
3. Profitability & Quality REPL
Gross Margin N/A -73.3%
Operating Margin 0.0% -167.0%
Net Profit Margin 0.0% -144.9%
Return on Equity (ROE) -115.8% -147.4%
4. Balance Sheet & Cash Flow EDIT
Cash Generation (TTM) -$246M -$110M
Cash Flow Margin N/A N/A
Net Cash / Leverage $181M Net Cash $79M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning REPL
Options Structure Phase BREAKOUT BREAKDOWN
Current IV / %ile 75.9% (8th %ile) 95.8% (38th %ile)
Put/Call OI Skew 0.01x (Call-Skewed) 0.29x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat EDIT
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Concentrated Oligopoly Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: REPL (6) vs EDIT (2)
Institutional Metric REPL EDIT Criterion Row Edge
Market Capitalization
Scale
$2.1B $336.5M Larger Scale REPL
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +37.4% Higher Growth EDIT
Operating Margin (TTM)
Profitability
0.0% -167.0% Higher Margin REPL
Net Profit Margin
Profitability
0.0% -144.9% Higher Margin REPL
Return on Equity (ROE)
Capital Efficiency
-115.8% -147.4% Higher ROE REPL
52-Week Range Position
Momentum
91% ($2–$24) 11% ($2–$4) Stronger Trend REPL
Beta / 30D Volatility
Risk Regime
2.10β · 100% Vol 2.32β · 102% Vol Lower Realized Risk REPL
Unified Institutional Score
Composite Signal
27.4 / 100 (SELL) 48.4 / 100 (HOLD) Higher Composite EDIT
Trailing 12M Revenue (USD)
Operating Scale
N/A $50M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -73.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 5.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$246M ($181M Net Cash) -$110M ($79M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon REPL +117.28 pp
REPL: +98.34% · EDIT: -18.94%
3M Horizon REPL +72.1 pp
REPL: +38.25% · EDIT: -33.85%
6M Horizon REPL +339.93 pp
REPL: +312.64% · EDIT: -27.29%
1Y Horizon REPL +164.87 pp
REPL: +139.87% · EDIT: -25.0%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on REPL vs EDIT. Trailing 12-month operating profitability (REPL 0.0% vs EDIT -167.0%) and valuation multiples (REPL N/M vs EDIT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

REPL ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-115.8% · N/M
EDIT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$50M
Gross Margin-73.3%
Op. Margin-167.0%
ROE / Fwd P/E-147.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
REPL BREAKOUT
98d in phase · OBV NEUTRAL
Current IV 75.9%
IV Percentile 8th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact REPL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EDIT BREAKDOWN
146d in phase · OBV NEUTRAL
Current IV 95.8%
IV Percentile 38th %ile
Put/Call OI Skew 0.29x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EDIT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
REPL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EDIT Moat Profile Concentrated Oligopoly Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $336.5M market capitalization and -167.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing

Investor FAQ REPL vs EDIT Key Questions & Quantitative Answers

As of Nov 16, 2026, Replimune Group, Inc. (REPL) captures the overall head-to-head institutional edge over Editas Medicine, Inc. (EDIT) on higher Unified Composite conviction (27.4/100 SELL vs. 48.4/100 HOLD) after splitting the core matrix 6–2 (led by Profitability & Quality, Options & Positioning), while EDIT wins 4–2 across the 6-pillar growth and valuation breakdown. REPL trades at $21.54 (N/M Forward P/E, 0.0% operating margin) versus EDIT at $1.91 (N/M Forward P/E, -167.0% operating margin). Composite vs. Pillar Nuance: While EDIT currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. REPL 27.4/100 SELL), REPL captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -167.0% operating margin) and revenue trajectory (+0.0% vs. +37.4% YoY). Technical & Structure Timing Caution: REPL trades in a Markup technical trend (BREAKOUT options phase, RSI 69.6); meanwhile EDIT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EDIT leads the Growth & Scale pillar: REPL posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with EDIT at +37.4% YoY revenue growth and +0.0% YoY earnings growth on $50M TTM revenue (-73.3% gross margin, -167.0% operating margin). On trailing 12-month operating scale, REPL generates N/A in USD-normalized revenue versus $50M for EDIT. In operating R&D and SG&A reinvestment, REPL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EDIT.

EDIT screens cheaper on headline valuation multiples. REPL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas EDIT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 5.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against REPL (-115.8% ROE) versus EDIT (-147.4% ROE) capital efficiency.

In options market volatility and institutional positioning, REPL carries 75.9% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (2.10β · 100% Vol realized risk). By comparison, EDIT carries 95.8% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.29x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.32β · 102% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.